Blood Gene Patterns and Plaque Buildup in Heart Arteries
Studies blood gene activity in adults with fatty plaque in heart arteries.
Plain-language title generated from the registry record
Registry title: Whole Blood Transcriptomic Signal According to Coronary Atherosclerotic Plaque Burden Assessed by CT Angiography
Key facts
- Where
- Ciudad Autónoma de Buenos Aire, ArgentinaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06194526, who can take part
Where in Argentina
- Clinica Sagrada FamiliaCiudad Autónoma de Buenos Aire, ArgentinaNo longer taking part
- Sanatorio Julio MendezCiudad Autónoma de Buenos Aire, ArgentinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- MultiplAI Health Limited
- Trial code
- NCT06194526
- Record updated
- 8 January 2024
- Original description
The present clinical study aims to identify transcriptomic patterns derived from whole blood samples related to coronary atherotic burden. Additionally, as a secondary analysis, the research team will explore the algorithm's ability to detect the presence of aortic disease and pro-inflammatory cardiometabolic alterations, such as hepatic steatosis and surrogate markers of coronary inflammation.Read full original descriptionShow less
Whole Blood Transcriptomic Signal According to Coronary Atherosclerotic Plaque Burden Assessed by CT Angiography: CORPLAQ-TRAIT Pilot Study
The present clinical study aims to identify transcriptomic patterns derived from whole blood samples related to coronary atherotic burden. Additionally, as a secondary analysis, the research team will explore the algorithm's ability to detect the presence of aortic disease and pro-inflammatory cardiometabolic alterations, such as hepatic steatosis and surrogate markers of coronary inflammation.
Inclusion: Men and women between 18 and 75 years, with a clinical indication to be evaluated by a CCTA due to suspected or known CAD; Signature of informed consent.
Exclusion: Previously known chronic renal or hepatic insufficiency; Implantation of drug-eluting stents in the last 12 months; Revascularization surgery (By-pass); Previous surgeries in the last 3 months; Severe trauma in the last 6 months, defined as one that involved bone fractures and/or surgical interventions; Temperature greater than 37.5°C recorded by a thermometer or any acute infection caused by viruses or bacteria confirmed by a health professional in the previous 30 days; Prior to the study: heart rate > 70 l/m or atrial fibrillation or frequent extrasystoles that in the opinion of the specialist physician will affect the quality of the cardiovascular imaging; Active chronic lung disease, defined as: exacerbated asthma, exacerbated COPD, or pulmonary fibrosis; Myocardial infarction, unstable angina, cerebrovascular accident, or vascular interventions (any territory) in the past 6 months; Indication of Angio-CT for congenital heart disease or Transcatheter Aortic Valve Replacement (TAVI); Presence/ diagnosis of heart failure symptoms or signs (ie. dyspnea, asthenia, edema) with objective evidence of pulmonary or systemic congestion at rest or with exercise in the last 6 months; Suprarenal insufficiency; Known active cancer disease or under treatment (acute or preventive), or history of cancer disease without criteria for cure; Diagnosis of active autoimmune disease or any pathology under immunosuppressive treatment; Other serious diseases with an estimated life expectancy of less than 12 months (according to the investigator's opinion); Left ventricular ejection fraction <50% confirmed by objective diagnostic methods (eg doppler echocardiogram); Severe valvulopathies, confirmed by objective diagnostic methods (eg doppler echocardiogram); Uncontrolled hyper or hypothyroidism; Ongoing pregnancy, postpartum period of less than 12 months or breastfeeding; Pacemaker/Cardio-Defibrillator Implantation.